Recent Updates
Recently added Catalysts
IMVT Positive Sentiment Score: 60/100

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Monday, May 11, 2026 1 min read
Key Takeaway: Immunovant (Nasdaq: IMVT) has announced that it will report its financial results for the fourth quarter and fiscal year ending March 31, 2026, on May 20, 2026. The company will also provide a business update during a conference call scheduled for 8:00 a.m. ET. This event underscores Immunovant's commitment to transparency and engagement with stakeholders.

Market Sentiment Analysis

POSITIVE FACTORS

  • Immunovant is delivering an update on its financial results and business strategy.
  • The company is advancing innovative therapies for autoimmune diseases.
  • The upcoming conference call reflects proactive communication with investors.

Full Press Release Details

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update at 8:00 a.m. ET on Wednesday, May 20, 2026.
To access the Roivant (Nasdaq: ROIV) conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “News & Events” in the Investors section of the Immunovant website at https://www.immunovant.com/investors/news-events/ir-calendar. The archived webcast will be available on Immunovant’s website after the conference call.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com.
keyur.parekh@roivant.com
stephanie.lee@roivant.com

Frequently Asked Questions

When will Immunovant report its financial results?

Immunovant will report its financial results on May 20, 2026.

How can I access the conference call for financial results?

You can register online via the provided registration link to access the call.

What is Immunovant's focus as a company?

Immunovant focuses on enabling normal lives for those with autoimmune diseases.

Where can I find the archived webcast of the call?

The archived webcast will be available on Immunovant's website after the call.

What technology is Immunovant developing?

Immunovant is developing therapies using anti-FcRn technology.

Tags: IMVT Viatris Investor Conferences Healthcare Immunovant financial results autoimmune diseases clinical-stage investors
Last updated: May 11, 2026